The Predictive Significance of the Advanced Lung Cancer Inflammation Index (ALI) in Patients with Melanoma Treated with Immunotherapy as Second-Line Therapy

References

• Bray FI, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582–588. doi:10.1093/annonc/mdz01130715153
   PubMed Web of Science ®Google Scholar
• Hodi FS, Chiarionsileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, Phase 3 trial. Lancet Oncology. 2018;19(11):1480–1492. doi:10.1016/S1470-2045(18)30700-930361170
   PubMed Web of Science ®Google Scholar
• Hodi FS, Kluger HM, Sznol M, et al. Abstract CT001: durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a Phase I trial. Cancer Res. 2016;76(5):999–1008. doi:10.1158/0008-5472.CAN-15-143926833127
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M, et al. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899.20303878
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, Mcmillan DC, et al. Cancer-related inflammation and treatment effectiveness. Lancet Oncology. 2014;15:11. doi:10.1016/S1470-2045(14)70263-3
   Web of Science ®Google Scholar
• Elinav E, Nowarski R, Thaiss CA, et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11):759–771. doi:10.1038/nrc361124154716
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867. doi:10.1038/nature0132212490959
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature0720518650914
   PubMed Web of Science ®Google Scholar
• Nakamura K, Smyth MJ. Targeting cancer-related inflammation in the era of immunotherapy. Immunol Cell Biol. 2017;95(4):325–332. doi:10.1038/icb.2016.12627999432
   PubMed Web of Science ®Google Scholar
• Kasahara N, Sunaga N, Tsukagoshi Y, et al. Post-treatment glasgow prognostic score predicts efficacy in advanced non-small-cell lung cancer treated with Anti-PD1. Anticancer Res. 2019;39(3):1455–1461. doi:10.21873/anticanres.1326230842182
   PubMed Web of Science ®Google Scholar
• Diem S, Schmid S, Krapf M, et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–181. doi:10.1016/j.lungcan.2017.07.02428838390
   PubMed Web of Science ®Google Scholar
• Tamiya M, Tamiya A, Hosoya K, et al. Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001). Invest New Drugs. 2019;37(6):1266–1273. doi:10.1007/s10637-019-00843-y31392549
   PubMed Web of Science ®Google Scholar
• Sadeghi M, Keshavarz-Fathi M, Baracos V, Arends J, Mahmoudi M, Rezaei N. Cancer cachexia: diagnosis, assessment, and treatment. Crit Rev Oncol Hematol. 2018;127:91–104. doi:10.1016/j.critrevonc.2018.05.00629891116
   PubMed Web of Science ®Google Scholar
• Peterson SJ, Mozer M. Differentiating sarcopenia and cachexia among patients with cancer. Nutr Clin Pract. 2017;32(1):30–39. doi:10.1177/088453361668035428124947
   PubMed Web of Science ®Google Scholar
• Jafri SH, Shi R, Mills G, et al. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review.. BMC Cancer. 2013;13(1):158. doi:10.1186/1471-2407-13-15823530866
   PubMed Web of Science ®Google Scholar
• Hua X, Chen J, Wu Y, et al. Prognostic role of the advanced lung cancer inflammation index in cancer patients: a meta-analysis. World J Surg Oncol. 2019;17(1):1–9. doi:10.1186/s12957-019-1725-230606220
   PubMed Web of Science ®Google Scholar
• Shibutani M, Maeda K, Nagahara H, et al. The prognostic significance of the advanced lung cancer inflammation index in patients with unresectable metastatic colorectal cancer: a retrospective study. BMC Cancer. 2019;19(1):241. doi:10.1186/s12885-019-5468-930885163
   PubMed Web of Science ®Google Scholar
• Topkan E, Mertsoylu H, Ozdemir Y, et al. Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy. Cancer Manag Res. 2019;11:8807–8815. doi:10.2147/CMAR.S22229731632140
   PubMed Web of Science ®Google Scholar
• Shiroyama T, Suzuki H, Tamiya M, et al. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer. Cancer Med. 2018;7(1):13–20. doi:10.1002/cam4.123429150906
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• Muscaritoli M, Anker SD, Argilés J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr. 2010;29:154–159. doi:10.1016/j.clnu.2009.12.00420060626
   PubMed Web of Science ®Google Scholar
• Jacobs NL, Holtan SG, Porrata LF, Markovic SN, Tefferi A, Steensma DP. Host immunity affects survival in myelodysplastic syndromes: independent prognostic value of the absolute lymphocyte count. Am J Hematol. 2010;85:160–163. doi:10.1002/ajh.2161820131304
   PubMed Web of Science ®Google Scholar
• Brkic FF, Kadletz L, Jank B, et al. Impact of pretherapeutic neutrophil-to-lymphocyte ratio, serum albumin, body-mass index, and advanced lung cancer inflammation index on clinical outcome in sinonasal squamous cell carcinoma. J Craniomaxillofac Surg. 2020;48(1):33–37. doi:10.1016/j.jcms.2019.11.01031810849
   PubMed Web of Science ®Google Scholar
• Park YH, Yi HG, Lee MH, et al. Prognostic value of the pretreatment advanced lung Cancer Inflammation Index (ALI) in Diffuse Large B cell lymphoma patients treated with R-CHOP chemotherapy. Acta Haematol. 2017;137(2):76–85. doi:10.1159/00045299128076862
   PubMed Web of Science ®Google Scholar
• Barth DA, Brenner C, Riedl JM, et al. External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients. Cancer Med. 2020;9(15):5473–5479. doi:10.1002/cam4.323332537935
   PubMed Web of Science ®Google Scholar
• Vilain RE, Menzies AM, Wilmott JS, et al. Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma. Clin Cancer Res. 2017;23(17):5024–5033. doi:10.1158/1078-0432.CCR-16-069828512174
   PubMed Web of Science ®Google Scholar
• Balatoni T, Mohos A, Papp E, et al. Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy. Cancer Immunol Immunother. 2018;67(1):141–151. doi:10.1007/s00262-017-2072-128988380
   PubMed Web of Science ®Google Scholar
• Forschner A, Battke F, Hadaschik D, et al. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study. J Immunother Cancer. 2019;7(1):180. doi:10.1186/s40425-019-0659-031300034
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Hellmann MD, Hamid O, et al. Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res. 2017;5(5):417–424. doi:10.1158/2326-6066.CIR-16-032528411193
   PubMed Web of Science ®Google Scholar
• Capone M, Giannarelli D, Mallardo D, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. 2018;6(1):74. doi:10.1186/s40425-018-0383-130012216
   PubMed Web of Science ®Google Scholar
• Bartlett EK, Flynn JR, Panageas KS, et al. High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy. Cancer. 2020;126(1):76–85. doi:10.1002/cncr.3250631584709
   PubMed Web of Science ®Google Scholar
• Laino AS, Woods D, Vassallo M, et al. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J Immunother Cancer. 2020;8(1):e000842. doi:10.1136/jitc-2020-00084232581042
   PubMed Web of Science ®Google Scholar